Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21183292 | 0.93 | BCHE (0.55) | BCHESTK17BSTK17ANPSR1TDP1 | |
| SCHEMBL10073542 | 0.91 | BCHE (0.44) | BCHESTK17BSTK17ANPSR1TDP1 | |
| SCHEMBL610056 | 0.89 | BCHE (0.46) | BCHESTK17BSTK17ANPSR1TDP1 | |
| SCHEMBL10047095 | 0.88 | BCHE (0.42) | BCHESTK17BSTK17ANPSR1TDP1 | |
| SCHEMBL28469810 | 0.81 | GDA (0.42) | BCHETDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL611824 | 0.78 | STK17B (0.47) | STK17BSTK17ANPSR1TDP1ATM | |
| SCHEMBL1965514 | 0.78 | XDH (0.47) | XDHPOLBMAPTKDM4E | |
| SCHEMBL2623143 | 0.77 | XDH (0.65) | BCHEXDHPOLBMEN1KMT2A | |
| SCHEMBL249648 | 0.76 | XDH (0.66) | BCHEXDHPOLBMEN1KMT2A | |
| SCHEMBL8535455 | 0.75 | XDH (0.67) | BCHEXDHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268607-B9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-05-13 | — | — | EP | disclosed |
| EP-2268607-B9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-05-13 | — | — | EP | disclosed |
| EP-2268607-B1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-02-18 | — | — | EP | disclosed |
| US-8895734-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895734-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8884008-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-8884008-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-10-30 | — | — | US | disclosed |
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-10-30 | — | — | US | disclosed |
| US-8859766-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-10-14 | — | — | US | disclosed |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-8680253-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-8680253-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2011-07-21 | — | — | US | disclosed |
| EP-2268607-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | Cti Bio (KR) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009113828-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009113828-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | BCHE 4726/4885STK17B 2616/4885STK17A 3336/4885 |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | BCHE 4726/4885STK17B 2616/4885STK17A 3336/4885 |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | BCHE 4726/4885STK17B 2616/4885STK17A 3336/4885 |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | BCHE 4726/4885STK17B 2616/4885STK17A 3336/4885 |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | BCHE 4726/4885STK17B 2616/4885STK17A 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.